Innovent Biologics, Inc.: Obesity trials
The registry lists 12 Obesity studies with Innovent Biologics, Inc. as lead sponsor. 4 are open to participants now and 0 have results posted.
Phase 1 6Phase 2 3Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of IBI3046 in Participants With Overweight or ObesityRecruitingNCT07809945Phase 1
- IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsRecruitingNCT07793019Phase 1
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingNCT07469800Phase 3
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingNCT06931028Phase 3
- A Study of IBI3032 in Chinese Participants With Overweight or ObesityActive, not recruitingNCT07170319Phase 1
- A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or ObesityCompletedNCT07160400Phase 1
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityActive, not recruitingNCT07000955Phase 1/2
- A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityActive, not recruitingNCT06862908Phase 2
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityCompletedNCT06184568Phase 3
- A Study of IBI362 9 mg in Chinese Adults With ObesityActive, not recruitingNCT06164873Phase 3
- A Study of IBI362 in Participants With Obesity or OverweightCompletedNCT05607680Phase 3
- Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsCompletedNCT04440345Phase 1/2